Newbury Pharmaceuticals (NEWBRY) Q3 2026 earnings summary

Executive summary

• Net revenue for Q3 increased 34% year-over-year to SEK 8.9 million, with nine-month revenue up 13% to SEK 29.1 million.

• EBITDA loss narrowed to SEK -4.0 million in Q3 from SEK -5.7 million last year; nine-month EBITDA was SEK -13.2 million.

• Operating cash flow for Q3 was SEK -10.3 million, and SEK -14.6 million for the nine-month period.

• Cash position at period end was SEK 14.7 million, supported by a SEK 30 million loan facility extension.

• 24 products launched in the Nordics, with a target of over 30 by end of 2026.

Financial highlights

• Q3 net revenue: SEK 8.9 million (Q3 last year: SEK 6.7 million); nine-month revenue: SEK 29.1 million (prior: SEK 25.7 million).

• Q3 EBITDA: SEK -4.0 million (prior: SEK -5.7 million); nine-month EBITDA: SEK -13.2 million (prior: SEK -10.4 million).

• Q3 operating result (EBIT): SEK -4.4 million (prior: SEK -6.2 million); nine-month EBIT: SEK -14.7 million (prior: SEK -11.8 million).

• Q3 result after tax: SEK -5.0 million (prior: SEK -6.6 million); nine-month result after tax: SEK -16.1 million (prior: SEK -13.1 million).

• International sales for the quarter and period were SEK 92 thousand, down from SEK 2.9 million.

Outlook and guidance

• Focus remains on reaching EBITDA breakeven as a foundation for long-term growth.

• Final quarter expected to benefit from additional product launches and increased tender activity.

• Expanding portfolio and improving gross margins are expected to offset fixed costs.

• SEK 30 million loan facility secured through June 2027 provides financial runway.